Pyrroloquinoline quinone disodium salt (PQQ) has been investigated in scientific studies for its potential anti-aging properties, primarily due to its role as a redox cofactor involved in mitochondrial function and cellular energy metabolism. Preclinical research in animals has shown that PQQ can stimulate mitochondrial biogenesis, enhance antioxidant defenses, and reduce markers of oxidative stress, which are processes commonly implicated in aging. Some small human clinical trials and pilot studies suggest PQQ supplementation may improve markers of mitochondrial function, reduce inflammation, and offer neuroprotective benefits, but these studies are generally limited in size, duration, and design quality.

There is no robust clinical evidence directly demonstrating that PQQ supplementation prevents aging or extends human lifespan. Most claims are based on mechanistic studies, animal research, and short-term biomarker changes in humans. While the scientific rationale for PQQ's potential is plausible and early data are intriguing, current human evidence is insufficient to justify its widespread use specifically for aging prevention. Larger, long-term, and well-controlled studies are needed to establish clinical efficacy and safety for this purpose. Therefore, the evidence supporting PQQ's use for aging prevention is weak to moderate (rated 2 out of 5).